Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca C Arend

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
Gynecologic Oncology|November 5, 2021
International gynecologic cancer society (IGCS) 2021 meeting reportMariam M AlHilli, Rebecca C Arend
Annals of Translational Medicine|August 15, 2020
Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancerJaclyn A Wall, Rebecca C Arend
Gynecologic Oncology|September 14, 2025
From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncologyMary M Mullen, Rebecca C Arend
Cancers|April 30, 2021
Assessing Preclinical Research Models for Immunotherapy for Gynecologic MalignanciesJhalak Dholakia, Carly Scalise, Rebecca C Arend
Molecular Cancer Therapeutics|May 5, 2018
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian CancerBayley A Jones, Sooryanarayana Varambally, Rebecca C Arend
Gynecologic Oncology Reports|June 12, 2025
Exploring T-cell bispecific antibodies in gynecologic malignancyEmily O'Brien, Christopher M Mayer, Rebecca C Arend
Gynecologic Oncology Reports|July 18, 2019
Checkpoint inhibitors in ovarian cancer: A review of preclinical dataDavid W Doo, Lyse A Norian, Rebecca C Arend
Oncotarget|January 17, 2019
Revisiting entinostat as an immune-potentiating adjuvantTyler R McCaw, Troy D Randall, Rebecca C Arend
Cancers|May 17, 2019
Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian CancerBrandon M Roane, Rebecca C Arend, Michael J Birrer
Expert Opinion on Investigational Drugs|May 16, 2020
The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancerJaclyn A Wall, Samuel J Klempner, Rebecca C Arend
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
Gynecologic Oncology|November 5, 2021
International gynecologic cancer society (IGCS) 2021 meeting reportMariam M AlHilli, Rebecca C Arend
Annals of Translational Medicine|August 15, 2020
Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancerJaclyn A Wall, Rebecca C Arend
Gynecologic Oncology|September 14, 2025
From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncologyMary M Mullen, Rebecca C Arend
Cancers|April 30, 2021
Assessing Preclinical Research Models for Immunotherapy for Gynecologic MalignanciesJhalak Dholakia, Carly Scalise, Rebecca C Arend
Molecular Cancer Therapeutics|May 5, 2018
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian CancerBayley A Jones, Sooryanarayana Varambally, Rebecca C Arend
Gynecologic Oncology Reports|June 12, 2025
Exploring T-cell bispecific antibodies in gynecologic malignancyEmily O'Brien, Christopher M Mayer, Rebecca C Arend
Gynecologic Oncology Reports|July 18, 2019
Checkpoint inhibitors in ovarian cancer: A review of preclinical dataDavid W Doo, Lyse A Norian, Rebecca C Arend
Oncotarget|January 17, 2019
Revisiting entinostat as an immune-potentiating adjuvantTyler R McCaw, Troy D Randall, Rebecca C Arend
Cancers|May 17, 2019
Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian CancerBrandon M Roane, Rebecca C Arend, Michael J Birrer
Expert Opinion on Investigational Drugs|May 16, 2020
The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancerJaclyn A Wall, Samuel J Klempner, Rebecca C Arend
Pageof 12